Loading patent…
AssigneesPfizer Inc., Bristol-Myers Squibb Company
InventorsSTEVEN LEE BENDER, GERALD FRIES CASPERSON, DANA DAN HU-LOWE, XIN JIANG, GANG LI, MICHAEL AIDAN NORTH, JIANYING WANG, GRANT WICKMAN, PETER BRAMS, HAICHUN HUANG, BRIGITTE DEVAUX, HAIBIN CHEN, DAWN M. TANAMACHI, KRISTOPHER TOY, LAN YANG, TIM W. SPROUL, MARK YAMANAKA
Estimating the term…
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein.
1-10. (canceled)
An isolated monoclonal antibody, or an antigen-binding portion thereof, that:
An isolated human full-length IgG1 antibody having at least one Fc region amino acid mutation, exhibiting greater antibody dependent cellular cytotoxicity (ADCC) than an identical antibody without the at least one Fc region amino acid mutation and capable of binding to human integrin α5β1 with a KD of 1×10−7 M or less.
An isolated monoclonal antibody or antigen-binding portion thereof that binds to human integrin α5β1 with a KD of 1×10−7 M or less and comprises a heavy chain variable region that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO:7.
Dependencies are inferred from the claim text.